natgillin/translations-raw huggingface dataset:
Aqueous suspension according to any of claims 1 to 13, characterized in that the anion of said water-soluble salt is selected from the group consisting of phosphate, dihydrogen phosphate, monohydrogen phosphate, oxalate, silicate, mixtures thereof and hydrates thereof, more preferably from the group consisting of phosphate, dihydrogen phosphate, monohydrogen phosphate, mixtures thereof and hydrates thereof, and most preferably from the group consisting of dihydrogen phosphate, monohydrogen phosphate, mixtures thereof and hydrates thereof. 
Postupak prema bilo kojem od zahtjeva 1 do 14, naznačen time da je anion navedene kiseline topive u vodi odabran iz skupine koja sadrži fosfat, dihidrogen fosfat, monohidrogen fosfat, oksalat, silikat, njihove mješavine i njihove hidrate, poželjnije iz skupine koja sadrži fosfat, dihidrogen fosfat, monohidrogen fosfat, njihove mješavine i njihove hidrate, te najpoželjnije iz skupine koja sadrži dihidrogen fosfat, monohidrogen fosfat, njihove mješavine 1 njihove hidrate.
The outer wall 16 is still in sealing contact with the peripheral part 13 of the base part 5. 
Vanjska stijenka 16 je stalno u nepropusnom dodiru s rubnim dijelom 13 osnovnog dijela 5.
Inhibition of SERT is one mechanism by which antidepressants such as fluoxetine (Prozac®) exert their therapeutic effects. 
Inhibicija SERT-a je mehanizam kojim antidepresivi poput fluoksetina (Prozac*) vrše svoje terapeutske učinke.
A pallet as claimed in claim 20, characterised in that said structure further comprises at least one seventh C-shaped component (116) consisting of a central portion and two terminal portions bent to further stabilize the connection between said fifth components (112) and sixth components (114). 
Paleta u skladu s patentnim zahtjevom 20, naznačena time što navedena struktura dodatno ima najmanje jednu sedmu komponentu u obliku slova C (116), koja se sastoji od središnjeg dijela i dva terminalna dijela svinuta da dodatno stabiliziraju vezu između navedenih petih komponenata (112) i šestih komponenata (114).
a light chain comprising an amino acid sequence as set out in SEQ ID NO: 34 and further comprising a heavy chain selected from: 
laki lanac, koji sadrži aminokiselinski slijed kao što je iznijet u SEQ ID NO: 34 i dodatno sadrži teški lanac, koji se bira između:
The fin deployment mechanism according to claim 1, wherein the fins are fixed to the base unit with a soldered joint. 
Mehanizam za razvijanje stabilizatora (1) prema zahtjevu 1, naznačen time da su stabilizatori (8) učvršćeni na osnovnu jedinicu (3) s lemljenim spojem.
The bacterial species Roseburia hominis for use in promoting gut health in a subject. The bacterial species Roseburia hominis for use in promoting Tregs cells and tolerance mechanisms in the immune system of a subject. 
Bakterijska vrsta Roseburia hominis za upotrebu prema zahtjevu 1 naznačena time što je bakterijska vrsta za upotrebu u unaprijeđenju Tregs ćelija i mehanizama tolerancije imunog sustava subjekta.
A method according to claim 1 or 2, wherein gene mosaics of a non-coding sequence, a partial gene or genes of at least 3 up to 20.000 base pairs are obtained. 
Metoda u skladu s patentnim zahtjevom 1 ili 2, pri čemu su dobiveni genski mozaicizmi nekodirajučih sljedova, djelomični geni ili geni od najmanje 3 do 20 000 parova baza.
wherein said functional fragment or homolog thereof has the ability of binding to cell surface death receptors and inducing apoptosis in mammalian cells; and domain (b) which is a sequence of an immunostimulating effector peptide selected from the group consisting of the pseudodimer of interferon gamma of SEQ. 
pri čemu navedeni funkcionalni fragment ili njegov homolog ima sposobnost vezanja za receptore smrti na staničnoj površini i induciranja apoptoze u stanicama sisavaca; i domenu (b) koja je sekvenca imunostimulirajućeg efektornog peptida izabranog iz grupe koju čine pseudodimer interferona gama SEQ.
In another embodiment, the stabilizer may further comprise at least one bulking agent, which may comprise dextran, maltodextrin, polyvinylpyrrolidone, hydroxyethyl starch, or combinations thereof. 
(b) najmanje jedno punilo pri čemu to najmanje jedno punilo sadrži dekstran, maltodekstrin, polivinilpirolidon, hidroksietil škrob ili njihove kombinacije ili
The invention relates to a process for the preparation of a compound of formula (I): or a tautomer, stereoisomer, or a pharmacologically acceptable salt of any of the foregoing, wherein: 
Postupak za pripremu spoja čija je formula (I): ili tautomera, stereoizomera ili neke farmakološki prihvatljive soli bilo kojeg od prije navedenih gdje je
In certain embodiments, the final concentration of the polysorbate 80 in the formulation is 0.01% to 10% polysorbate 80 weight/volume of the formulation. 
(ii) polisorbat 80 u konačnoj koncentraciji od 0,01% do 0,05% polisorbata 80, težinski, po volumenu formulacije i
The extended release dosage form of claim 9, wherein the opioid analgesic is hydromorphone hydrochloride and the dosage form comprises from about 1 mg to about 100 mg of hydromorphone hydrochloride, preferably 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 24 mg, 32 mg, 48 mg or 64 mg of hydromorphone hydrochloride. 
Postupak prema zahtjevu 37, naznačen time da je opioidni analgetik hidromorfon hidroklorid i da oblik davanja sadrži od oko 1 mg do oko 100 mg hidromorfon hidroklorida.
or a pharmaceutically acceptable salt thereof. The compound according to claim 1 wherein the compound is selected from the group consisting of: 
CH. ili njegova farmaceutski prihvatljiva sol. Spoj u skladu s patentnim zahtjevom 1, naznačen time što se spoj bira iz skupine koju čine:
Thus the disclosure provides a method for immunizing a patient against influenza virus, comprising steps of (i) administering to a subject an immunogenic composition comprising hemagglutinin antigen from a first clade of H5 influenza A virus, and then (ii) administering to the subject an immunogenic composition comprising hemagglutinin antigen from a second clade of H5 influenza A virus, wherein the first and second clades are different from each other. 
Imunogeni pripravak koji sadrži antigen hemaglutinina iz prvog klada H5 virusa influence A, naznačen time da je za uporabu u postupku imunizacije subjekta protiv virusa influence koji sadrži korake (i) davanja subjektu imunogenog pripravka koji sadrži antigen hemaglutinina iz prvog klada H5 virusa influence A, te zatim (11) davanja subjektu imunogenog pripravka koji sadrži antigen hemaglutinina iz drugog klada H5 virusa influence A, pri čemu su prvi i drugi klad međusobno različiti, te gdje:
Optionally, the coating composition may also include one or more of the following: from 0.05% to %% antimicrobrials such as triclosan and more preferably methylparaben, a fungicide from 50 to 5000 parts per billion such as TBZ, SOPP, or Imalzalil, and a plasticizer such as glycerin or polysorbate from 0.1 % to 20% to the weight of polyvinylidene chloride copolymer in the water based emulsion. 
Izborno, oblagajuća kompozicija također može sadržavati jedan ili više od sljedećih: od 0.05% do %% antimikrobnih sredstava kao što je triklosan i poželjnije metilparaben, fungicid od 50 do 5000 dijelova na milijardu kao što je TBZ, SOPP ili Imalzalil, i plastifikator kao što je glicerin i polisorbat od 0.1% do 20% prema masi poliviniliden klorid kopolimera u emulziji na bazi vode.
The total amount of such organic material in the aqueous medium prior to the addition of said surface-treated calcium carbonate, evaluated based on the Chemical Oxygen Demand (COD), is preferably from 1 000 to 5 000 mg O2/dm3, as measured according to the measurement method provided in the Examples section herebelow. 
Postupak prema bilo kojem od zahtjeva 21 ili 22, naznačen time da je ukupna količina organskog materijala u vodenom mediju prije dodavanja navedenog površinski obrađenog kalcijevog karbonata, procijenjena na temelju kemijske potrošnje kisika (Chemical Oxygen Demand (COD)), te je od 1000 do 5000 mg O,/dm'.
A nucleic acid encoding a bispecific protein, comprising: 
Bispecifični protein, koji sadrži:
The treatment and/or prevention method according to (35), characterized in that the osteoporosis is postmenopausal osteoporosis, senile osteoporosis, secondary osteoporosis due to the use of a therapeutic agent such as a steroid or an immunosuppressant, or osteoporosis accompanying rheumatoid arthritis. 
Antitijelo ili njegov funkcionalni fragment ili preparati za uporabu sukladno zahtjevu 27 ili uporaba sukladna zahtjevu 27, karakterizirani time da je osteoporoza postmenopauzalna osteoporoza, staračka osteoporoza, sekundarna osteoporoza uzrokovana uporabom terapeutika kao što su steroidi ili imunosupresivi, ili osteoporoza koja prati reumatoidni artritis.
According to the invention, the beam-like block of wood is watered and/or tempered prior to the cutting, whereby the watering and/or tempering preferably is carried out at an increased temperature, preferably at a temperature of > 60 °C, more preferred at a temperature of > 70 °C, in particular at a temperature between 75 and 85 °C. 
U skladu s ovim izumom, blok od drva koji ima oblik grede se potapa u vodu prije rezanja, pri čemu je poželjno da se namakanje izvodi na povišenoj temperaturi, poželjno na temperaturi od > 60"C, još poželjnije na temperaturi od > 70""C, naročito na temperaturi između 75 i $5%C.
The monolithic radiant panel arrangement as claimed in claim 1, wherein the monolithic radiant panel (100) is coated with a material such that the monolithic radiant panel (100) has an emissivity of about 0.90 to about 0.99. 
Sustav s monolitnim radijativnim panelom u skladu s patentnim zahtjevom 1, naznačen time što je monolitni radijativni panel (100) obložen takvim materijal da monolitni radijativni panel (100) ima emitivnost od otprilike 0,90 do otprilike 0,99.
The method of claim 1, wherein a compound of the general formula (1) or a salt thereof is selected from the group consisting of the following compounds: 
Spoj prema patentnom zahtjevu 3, naznačen time što je odabran iz skupine koja sadrži slijedeće spojeve:
Use according to claim 17 for the preparation of a medicament to treat sleep disorders, sleep apnea, sleep induced apnea, diurnal somnolence, stress, migraine, headache, pain, psychotropic disorders, asthma, bronchitis, rhinitis, tracheitis, gastric ulcers, duodenal ulcers, ulcerative colitis, Crohn's disease, irritable bowel syndrome, cystitis, metritis, urinary and faecal incontinence, urticaria, itching, arthritis, conjunctivitis, premenstrual syndrome, prostatic inflammations, genital disorders, rheumatic and ocular conditions, sialorrhea, convulsion, depression, disorders of the hypothalamohypophyseal secretion, the cerebral circulation and the immune system. 
Upotreba prema zahtjevu 18, za pripravu medikamenta za liječenje poremećaji spavanja, apneje u snu, apneja inducirana snom, dnevna uspavanosti, stresa, migrene, glavobolje, bol, psihotropnih poremećaja, astme, bronhitisa, rinitisa, traheitisa, čireva na želucu, ulcerativni kolitisa, Crohn'ove bolesti, sindroma iritabilnog crijeva, cistitisa, metritisa, urinalne 1 fekalne inkontinencije, urtikarije, svraba, artritisa, konjunktivitisa, predmenstrualnog sindroma, upale prostate, genitalnih poremećaai, reumatskih 1 očnih stanja, sijaloreje, konvulzije, depresije, poremećaja hipotalamo-hipofizne sekrecije, moždane cirkulacije i imunog sustava,
increase of serum HDL cholesterol levels of at least 2%, at least 2.5%, at least, 3%, at least 3.5%, at least 4%, at least 4.5%, at least 5% or at least 5.5% relative to a predose level upon administration to a subject, particularly when administered in a dose of about 150 mg E2W, little or no measurable effect on troponin levels upon administration to a subject, increase of one or more of: Total-Cholesterol levels, ApoB levels, non HDL-C levels, Apo-B/ApoA-1 ratio, upon administration to a subject. 
(b) povećanje razina HDL kolesterola u serumu od barem 2%, barem 2.5%, barem 3%, barem 3.5%, barem 4%, barem 4.5%, barem 5% ili barem 5.5% u odnosu na razinu prije doziranja nakon davanja subjektu doze od 150 mg E2W; (c) smanjenje jednog ili više od: razina ukupnog kolesterola, razina ApoB, razina ne HDL-C, omjera ApoB/ApoA-1, nakon davanja subjektu.
The peptide according to Claim 1, wherein said peptide includes non-peptide bonds. 
Peptid u skladu s patentnim zahtjevom 1, pri čemu peptid uključuje nepeptidne veze.
• addition of the powdered raw materials consisting of milk powder, starch, salt and vanillin by keeping the temperature constant at 30°C and effectively dissolving within fluid raw materials through 1000-3000 rpm agitation speed without pellet formation, 
dodavanje sirovina u prahu koje se sastoji od mlijeka u prahu, škroba, soli i vanilije održavajući temperaturu konstantnom na 30%C i učinkovito otapanje unutar tekućih sirovina miješanjem brzinom od od 1.000-3.000 ob/min bez stvaranja peleta.
to form a compound of formula [52] wherein R1, R2, R3, and R6 are defined above; and 
kako bi se dobilo spoj formule [52] [image], gdje R1, R2, R3, i R6 su definirani gore; i
means for switching between a first analog input channel and a second digital input channel, these channels carrying frequency offset estimate signals for analog and digital communication signals, respectively; 
- < sklop (80) za zamjenu između prvog analognog ulaznog kanala i drugog digitalnog ulaznog kanala, pri čemu ti kanali prenose signale procijenjene odlazne frekvencije za analogne, odnosno, digitalne komunikacijske signale;
A pharmaceutical composition according to claims 15 or 16, characterized in that it comprises, in addition, as a combination or conjugation product for use in a simultaneous, separated or extended fashion, a cytotoxic/cytostatic agent, a cellular toxin and/or a radioisotope. 
Pripravak prema patentnim zahtjevima 15 ili 16, naznačen time da dodatno kao kombinacijski ili konjugirani produkt za istodobnu, odvojenu ili produljenu upotrebu sadrži citotoksično/citostatsko sredstvo, stanični toksin i/ili radioizotop.
E is a methyl linker which is substituted by aminomethyl, wherein the amino group of the aminomethyl is unsubstituted, or mono- or disubstituted by LA, or E is a methyl linker which is substituted by (azetidin-1-yl)methyl, in Subformula 10 
E je metilna poveznica koja je supstituirana s aminometilom, pri čemu je amino skupina od aminometila nesupstituirana, ili mono- ili disupstituirana s
<4> a C1-8 alkanoyl group which may be substituted by substituent(s) selected from the group consisting of [1] a (C1-8 alkyl)m8k4-amino group and [2] a halogen atom, 
<4> Cia alkanoilna skupina, koja može biti supstituirana s jednim ili više supstituenata, koje se bira iz skupine koju čine [1] skupina (C1.g alkil),ygka-amino i [2] atom halogena, mš8k4: 0-2,
The device according to claim 22, wherein said guide means (44) comprise at least a stepped guide profile comprising two location surfaces (44a, 44b) and a stop ledge (44c) connected by two axial profile portions (44d, 44e). 
Uređaj u skladu s patentnim zahtjevom 22, naznačen time, da kotači (44) imaju najmanje stepenasti profil koji sadržava dvije površine za postavljanje (44a, 44b) 1 greben za zaustavljanje (44c) koji su povezani s pomoću dva aksijalna dijela profila (44d, 44e).
The pharmaceutical composition of claim 32, wherein the corticosteroid is fluticasone propionate with a particle size of less than 5 microns, the pharmaceutically acceptable carrier is silicified microcrystalline cellulose, the rapidly dispersing microgranules comprise mannitol and crospovidone, and the composition further comprises a free-flowing sugar alcohol which is spray-dried mannitol, and a lubricant which is sodium stearyl fumarate. 
pripremanje mljevene pred-mješavine 1 miješanjem farmaceutski prihvatljivog nosača, kortikosteroida, i glidanta u blenderu i zatim mljevenjem rezultirajuće smjese kroz mlin za fino mljevenje opremljen sitom sa otvorom mreže 30, izborno pri čemu je farmaceutski nosač silicificirana mikrokristalna celuloza, kortikosteroid je mikronizirani flutikazon propionat i glidant je koloidni silicij dioksid;
21, when opening the packaging with an angle of 180° as shown, the level of the back part 71 between the two hinges is higher than the level of the two sides 64, 65 of the inner part. 
Kao što se vidi na slici 21, kada se otvori pakiranje za kut od 180", kao što je prikazano, nivo stražnjeg dijela 71 između dva panta viši je od nivoa na kojemu su dvije strane 64, 65 unutarnjeg dijela.
The formulation was prepared by using a suitable stainless steel tank, provided with a thermosetting system and stirrer. 
Formulacija je pripremljena koristeći odgovarajuću posudu od nehrđajućeg čelika, sa sustavom za podešavanje temperature i mješalicom.
A fifth aspect of the invention relates to the use of a medium according to the invention for the maintenance of cells in culture during production phase of a polypeptide of interest. 
Peti se aspekt izuma odnosi na uporabu medija sukladno izumu za održavanje stanica u kulturi tijekom produkcijske faze proteina od interesa.
An image processing apparatus for processing an image obtained by fluoroscopying a subject, the image processing apparatus includes: a band-image generating device configured to generate a band image by extracting a part of frequency components in an original image with a figure of the subject appearing therein; 
uređaj za stvaranje slike na traci (12) koji ima konfiguraciju za stvaranje slike na traci pomoću ekstrakcije dijela frekvencijskih komponenti u originalnoj slici (P0) s likom pojedinca koji se pojavljuje na toj slici;
ii) loading said generator mixture onto a strong base anion exchange resin; 
ii) unos navedene smjese za generiranje na jako bazičnu anionsku izmjenjivačku smolu;
The method of claim 6, wherein the subsets to be generated are determined using non-zero subset flags, and the subsets are generated by applying the inverse scan pattern to the significant flags, the coefficient signs and the coefficient levels. 
Postupak prema Zahtjevu 6, gdje se podskupovi koje je potrebno generirati određuju korištenjem oznake podskupa različitog od nule koji ukazuje da li podskup sadrži koeficijente različite od nule ili ne, 1 gdje su podskupovi generirani primjenom obrasca inverznog skeniranja na značajne oznake, znakove koeficijenata i razine koeficijenata.
OWT 5 is heated by high-frequency currents in the following way. 
CNI 5 se zagrijava strujama visoke frekvencije na sljedeći način.
5,895,051) discloses acetylphenols, which are useful as antiobesity and antidiabetic compounds. 
5,895,051) otkrivaju acetilfenole, koji su korisni kao spojevi protiv pretilosti i antidijabetični spojevi.
A peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 4 and 5, wherein said peptide is 100 or less, 50 or less, 20 or less, or 10 or less amino acids long. 
Peptid koji sadrži aminokiselinsku sekvencu odabranu iz skupine sastavljene od SEK ID BR: 3, 4 i 5, naznačen time, da je navedeni peptid dužine 100 aminokiselina ili manje, 50 aminokiselina ili manje, 20 aminokiselina ili manje, ili 10 aminokiselina ili manje.
A method as defined in claim 19 wherein the sample is from an HIV-1 infected patient or wherein the sample is from an AIDS vaccine recipient. 
Postupak u skladu s patentnim zahtjevom 12, naznačen time što je uzorak dobiven iz pacijenta zaraženog virusom HIV-1 ili, što je uzorak dobiven iz primatelja cjepiva protiv AIDS-a.
the gain of the amplifier (102) is adjusted by the microcontroller unit (104) according to said pre-stored values for different levels of sun exposure signal, operating temperatures and measured time lapses between changes of the monitored sun exposure signal; 
- < pojačanje pojačala (102) podešeno je mikrokontrolerom (104) u skladu sa spomenutim prethodno pohranjenim vrijednostima za različite razine signala izloženosti suncu, radne temperature i izmjerene vremenske razmake između promjena promatranog signala izloženosti suncu;
optionally, selecting a modified continuous diploid avian cell line expressing said recombinant proteins or peptides; and 
odabir tih genetički modificiranih ptičjih staničnih linija koje eksprimiraju rekombinantne proteine ili peptide; i
The tablet of any one of claims 1-4 wherein the total weight of the first layer is greater than 225 mg. 
Tableta zahtjeva 6 gdje je ukupna masa prvog sloja 275 ± 75 mg, prije svega veća od 225 mg, a posebno je 275 ± 50 mg.
Multi pocket instruction bag according to claim 12, wherein the multi pocket instruction bag, preferably the pockets of the multi pocket instruction bag are provided with signs, symbols, letters, numbers, and/or pictures which indicate the user in which sequence the pockets, more in particular the content of the pockets, have to be consulted and/and or are to be used. 
Komplet dijelova u skladu s patentnim zahtjevom 11, naznačen time što vrećica za upute s više džepova (550), gdje po mogućnosti džepovi vrećice za upute s više džepova (550) sadrže znakove, simbole, slova, brojke i/ili slike koje pokazuju korisniku kojim redoslijedom treba konzultirati i/ili upotrebljavati džepove, specifičnije sadržaj džepova.
The process according to one of the preceding claims, wherein the polymeric flocculant is cationic. 
Postupak prema jednom od prethodnih zahtjeva, pri čemu je polimerni flokulant amonski i/ili kationski.
A pharmaceutical dosage form comprising a pharmaceutical composition according to clause 15, wherein the pharmaceutical dosage form comprises 5 mg to 500 mg of compound represented by Formula (III). 
Farmaceutska dozna forma sadržeći farmaceutski sastav prema zahtjevu 11, naznačeno time da farmaceutska dozna forma sadrži 5 mg do 500 mg spoja prikazanog Formulom (III).
A combination for use according to any preceding claim wherein the PI3K-a inhibitor is a compound of Formula I wherein A represents a heteroaryl selected from the group consisting of: 
Farmaceutska kombinacija za uporabu prema zahtjevu 4 ili zahtjevu 7, naznačena time što je proliferativna bolest rak debelog crijeva.
The composition according to claim 7 or 8, wherein said at least one additional compound is baclofen or mifepristone. 
Sastav u skladu s patentnim zahtjevom 7 ili 8, pri čemu je navedena barem jedna dodatna aktivna tvar baklofen ili mifepriston.
Method as claimed in claim 1, characterized in that the underwater section (12) with the cradle (21) are floated to within the range of a shore-based crane using buoyancy control, by which shore-based crane the underwater section (12) with the cradle (21) are picked up. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se podvodni dio (12) s gondolom (21) dopluta u doseg obalnog krana kontrolom uzgona, gdje se podvodni dio (12) s gondolom (21) podigne navedenim obalnim kranom.
The process of claim 3, which is for the preparation of a compound represented by formula (V): or a salt thereof, comprising the steps of: 
Postupak za pripremu spoja predstavljenog formulom (V): naznačen time što sadrži korake:
positioning a mold (12) proximate a surface of a substrate (10), such that the surface is in communication with a cavity of the mold (12); 
postavljanje kalupa (12) blizu površine supstrata (10), tako da je površina u vezi sa šupljinom kalupa (12);
Use according to claim 19 wherein said method further comprises the step of: determining the blood GLP-1 level in a biological sample obtained from a mammal, said mammal having been administered with a compound which stimulates functionality of the receptor in step (b); 
(c) određivanja nivoa GLP-1 u krvi u biološkom uzorku dobivenom iz sisavca, pri čemu je navedenom sisavcu bio primjenjen spoj koji stimulira funkcionalnost receptora iz koraka (b); pri čemu je sposobnost test spoja da poveća nivo GLP-1 u krvi u sisavcu nadalje indikativna da je test spoj GLP-1 sekretogog.
An aqueous paracetamol solution for perfusion according to claim 4, wherein the buffer is sodium citrate-acetate. 
Vodena otopina paracetamola za perfuziju sukladno patentnom zahtjevu 4, naznačena time, da je pufer natrijev citrat-acetat.
The dosage form according to claim 1 or 2 wherein the fluoxetine is fluoxetine hydrochloride. 
Oblik doziranja u skladu s patentnim zahtjevom 1 ili 2 pri čemu je fluoksetin fluoksetin hidroklorid.